GCP
ACHN

GSA Capital Partners’s Achillion Pharmaceuticals ACHN Stock Holding History

GSA Capital Partners’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-169,369
Closed -$501K – 1879
2019
Q1 		$501K Sell
169,369
-34,600
-17% -$85K 0.05% 696
2018
Q4 		$324K Sell
203,969
-55,200
-21% -$156K 0.04% 793
2018
Q3 		$954K Buy
259,169
+15,800
+6% +$47.1K 0.05% 713
2018
Q2 		$689K Buy
+243,369
New +$829K 0.03% 974
2018
Q1 		– Sell
-133,058
Closed -$383K – 1939
2017
Q4 		$383K Sell
133,058
-183,842
-58% -$668K 0.02% 1084
2017
Q3 		$1.42M Sell
316,900
-70,358
-18% -$312K 0.1% 307
2017
Q2 		$1.78M Buy
387,258
+109,558
+39% +$440K 0.12% 204
2017
Q1 		$1.17M Buy
277,700
+66,673
+32% +$277K 0.06% 542
2016
Q4 		$872K Buy
211,027
+169,679
+410% +$902K 0.05% 646
2016
Q3 		$335K Buy
41,348
+30,050
+266% +$256K 0.02% 1298
2016
Q2 		$88K Buy
+11,298
New +$96.9K ﹤0.01% 1679
2015
Q2 		– Sell
-12,927
Closed -$127K – 2288
2015
Q1 		$127K Buy
+12,927
New +$161K 0.01% 1994

Other funds holding ACHN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

GSA Capital Partners's ACHN Position: Q2 2019 in Review

GSA Capital Partners sold out of Achillion Pharmaceuticals (ACHN) in Q2 2019, closing a stake of 169,369 shares — an estimated $501K sold.

GSA Capital Partners first reported a position in ACHN in Q1 2015 and held it in 12 quarters. The position peaked at $1.78M in Q2 2017. 114 funds tracked by Wall St. Rank hold ACHN as of Q2 2019.

  • GSA Capital Partners reported no remaining Achillion Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • GSA Capital Partners sold 169,369 Achillion Pharmaceuticals shares in Q2 2019, an estimated $501K.
  • GSA Capital Partners first reported a position in Achillion Pharmaceuticals in Q1 2015 and held it in 12 quarters.
  • GSA Capital Partners's Achillion Pharmaceuticals position peaked at $1.78M in Q2 2017.
  • 114 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q2 2019.

Based on GSA Capital Partners's 13F filing for Q2 2019, filed 6 Aug 2019.